High Hopes and Dilemmas for a Cervical Cancer Vaccine

  title={High Hopes and Dilemmas for a Cervical Cancer Vaccine},
  author={Jon Cohen},
  pages={618 - 621}
  • Jon Cohen
  • Published 29 April 2005
  • Medicine
  • Science
As two vaccines against a sexually transmitted virus approach the market, public health experts are debating who should receive them--women, boys, or girls--and how to make them affordable in developing countries where the need is highest. 
Gardasil: first vaccine for human papillomavirus infection
In the New products review, Steve Chaplin presents the clinical data relating to its efficacy and Dr Anne Szarewski comments on the implications of the proposed immunisation programme.
The Case for Vaccinating Boys against Human Papillomavirus
If herd immunity against the most carcinogenic strains of HPV could be more rapidly and efficiently achieved by vaccinating everyone at risk for being a carrier, it logically follows that vaccine policy should expand to include boys and men.
HPV vaccine: Cervarix
  • A. Szarewski
  • Biology, Medicine
    Expert opinion on biological therapy
  • 2010
Cervarix has been shown to have high efficacy against disease associated with both HPV-16 and HPV-18, and its antibody response profile allows for optimism regarding the duration of immunity.
HPV vaccine development: A case study of prevention and politics
  • J. L. Grimes
  • Biology
    Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology
  • 2006
This case study describes the evolution of the understanding of HPV infection and its causative link to cervical cancer, the establishment of viable HPV vaccine candidates, and various issues related to HPV vaccine implementation.
New Approaches to Prophylactic Human Papillomavirus Vaccines for Cervical Cancer Prevention
These second-generation vaccines could also allow affordable immunization of women in developing countries, where the incidence of cervical cancer is high, and could aid in decreasing cost and increasing ease of use and breadth of protection.
Human papillomaviruses vaccine: a dermatologic perspective.
Dermatologists in India recognize a great many cases of anogenital warts, and afflicted individuals may be at increased risk of coinfection with oncogenic HPV types, so dermatologists are in a position to identify potential carriers of oncgenic HPV types in the population.
Prophylactic HPV Vaccines
This review summarizes the clinical studies that led to assess the prophylactic power of the present HPV vaccines and discusses some open questions and controversy on cervical cancer prevention in relation with the HPV vaccine.
Que hay en el horizonte sobre el virus del papiloma humano, vacunas y el control del cáncer cervical
How HPV vaccines have been developed and which aspects should be taken into consideration for implementation of an HPV vaccination program to prevent cervical cancer are explored.
Translational Mini‐Review Series on Vaccines:
Monitoring of human papillomavirus vaccination
Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most (cost‐)effective strategies for cancer control.
The Human Papillomavirus Vaccine in Canada
In conjunction with continued screening programs, the HPV vaccine offers the potential to dramatically reduce the burden of cervical cancer in Canada, and to do so in a cost-effective manner.